Sectors
AVIR
Atea Pharmaceuticals, Inc.
4.83
4 x 4.80
4 x 4.89
bid
ask
-
0.04
0.82%
10:00 AM
timesize
| Ytd | 35.29% | |
| 1y | 40.82% |
4.79
day range
4.89
2.78
52 week range
6.45
| Open | 4.81 | Prev Close | 4.87 | Low | 4.79 | High | 4.89 | Mkt Cap | 389.73M |
| Vol | 12.74K | Avg Vol | 324.88K | EPS | -2.11 | P/E | -2.31 | Forward P/E | -2.12 |
| Beta | 0.31 | Short Ratio | 14.25 | Inst. Own | 71.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.58 | 200-d Avg | 4.28 | 1yr Est | 7.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.5 | -0.37 | 0.13 | 26.00% |
| 2024-08-07 | 2024-06 | -0.77 | -0.48 | 0.29 | 37.66% |
| 2024-08-07 | 2024-06 | -0.77 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.61 | -0.75 | -0.14 | -22.95% |
| 2024-05-14 | 2024-03 | -0.61 | N/A | N/A | N/A |
| 2024-02-28 | 2023-12 | -0.44 | -0.47 | -0.03 | -6.82% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-13 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
| 2023-08-10 | JP Morgan | Downgrade | Neutral | Underweight |
| 2023-03-16 | JP Morgan | Upgrade | Neutral | |
| 2023-01-27 | SVB Leerink | Upgrade | Market Perform | |
| 2023-01-24 | Morgan Stanley | Upgrade | Underweight | |
| 2022-08-15 | Morgan Stanley | Upgrade | Underweight |
Profile
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-13 | ADAMS JEROME M. M.D. | Director | 33.15K | Conversion of Exercise of derivative security |
| 2024-12-09 | BERGER FRANKLIN MILAN | Director | 451.90K | Sale |
| 2024-01-31 | CORCORAN ANDREA J | Chief Financial Officer | 670.21K | Sale |
| 2024-06-13 | DUNCAN BARBARA GAYLE | Director | 33.15K | Conversion of Exercise of derivative security |
| 2024-01-31 | FOSTER WAYNE CPA | Officer | 20.86K | Sale |
| 2024-01-31 | HORGA MARIA ARANTXA | Officer | 25.66K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 8.99M | 29.22M | 10.64% |
| 2024-09-29 | BML Capital Management, LLC | 6.65M | 21.61M | 7.87% |
| 2024-09-29 | FMR, LLC | 6.62M | 21.51M | 7.84% |
| 2024-09-29 | EcoR1 Capital, LLC | 5.44M | 17.69M | 6.44% |
| 2024-09-29 | Vanguard Group Inc | 4.85M | 15.77M | 5.74% |
| 2024-09-29 | Tang Capital Management, LLC | 4.61M | 14.97M | 5.45% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.36M | 7.68M | 2.80% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.98M | 6.43M | 2.34% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.28M | 4.15M | 1.51% |
| 2024-10-30 | Fidelity Growth Company Fund | 961.77K | 3.13M | 1.14% |
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 805.35K | 2.62M | 0.95% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 769.60K | 2.50M | 0.91% |